Pluristyx, an advanced therapy tools and services biotechnology company, and Accelerated Biosciences, a regenerative medicine innovator in the use of proprietary human trophoblast stem cells (hTSCs), signed an agreement for Pluristyx to manufacture clinical grade hTSC banks under Good Manufacturing Practices (GMP). Accelerated Biosciences will use and make these stem cell banks available to commercial partners for further manufacturing of advanced biologic and cellular therapies. hTSCs have unique legal, ethical, and intellectual property advantages, including a high expansion capacity and a unique genetic identity not associated with any person or embryo, making them the ideal starting material for manufacturing the next generation of advanced therapies.

“We are gratified by Accelerated Biosciences’ choice of Pluristyx as their CDMO partner for GMP manufacturing,” said Benjamin Fryer, CEO, Pluristyx. “We are excited to be manufacturing clinical-grade cell banks for use as a unique starting source for the next generation of cell-based advanced therapies. This work demonstrates our commitment to providing the highest quality cells today for clinical development of tomorrow’s novel advanced therapies.”

Yuta Lee, CEO of Accelerated Biosciences, said, “We recognized early on that there is an unmet need for an ethical, clinical-grade, pluripotent stem cell source with complete regulatory compliance documentation from donor consent to GMP release. To meet this need, we aim to make the hTSC source readily available to industry partners in order to accelerate cures to market. We are grateful to the dedicated team at Pluristyx for making this complex process simple. We look forward to doing our part to advance the cell and gene therapy industry.”